The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Advocacy Team Celebrates Healthcare Fixes, Prepares to Face New Threats

Advocacy Team Celebrates Healthcare Fixes, Prepares to Face New Threats

March 1, 2018 • By Angus Worthing, MD, FACP, FACR

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Regarding the drug-pricing system: The ACR encourages lawmakers and regulators to address the problems of the PBM–pharma relationship, in which rebate payments encourage higher prices, not lower prices. The good news: Lawmakers are acting. Congress continues to look into PBMs; 17 state bills have been introduced; and on Feb. 23, Virginia passed the country’s first PBM legislation of 2018.

You Might Also Like
  • ACR Leaders Outline Advocacy Victories, Threats
  • Challenges Rheumatologists Will Face in 2017
  • ACR Leads Coalition Response to HHS Proposed Drug Pricing Threats
Also By This Author
  • Keeping the Pressure on Congress: ACR Opposes Medicare Payment Adjustment Plan, Executive Order

Regarding biosimilars: The ACR, alongside state and federal lawmakers, advocates for a smooth transition to an era of less expensive biologics that provide safe, effective treatments that are accessible to more people. Also, in order to provide useful educational content, on Feb. 7, the ACR published a biosimilars white paper in Arthritis & Rheumatology. It was an honor to participate in this project, with the aim of providing information on the scientific, clinical and economic issues surrounding biosimilars. The ACR biosimilars white paper is open access—please read and share it.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Regulatory Advocacy
Aside from your advocacy team’s efforts on Capitol Hill, I’m glad to report that the ACR has expanded its efforts to influence federal agencies, such as the HHS, CMS and FDA, on behalf of our profession and our patients. In 2017, the ACR more than doubled the number of letters submitted to federal agencies. Topics varied. Example: As Congress appears to be backing off from overarching efforts to repeal and replace Obamacare, the Trump administration continues to propose regulatory reforms that will affect our patients’ access to continuous health insurance and coverage for important services and treatments. The ACR has written several letters to federal policymakers thus far in 2018 about promoting healthcare choice and competition and reducing out-of-pocket costs for prescriptions. We also supported the FDA’s plan to close a loophole in drug development for pediatric orphan diseases. You can check out the ACR letters to the U.S. government here.

Committee Volunteer Acknowledgments
I would like to give shout-outs to all of our dedicated volunteers, including the following:

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
  • Tamar Rubenstein, MD, Chris Morris, MD, Ethan Craig, MD and Chris Phillips, MD, and Ms. Karla Jones, RN, MS, CPNP, along with other ACR leaders, who comprise a new working group that write the comment letters to federal agencies described above;
  • Zach Wallace, MD, the ACR’s Government Affairs Committee (GAC) liaison to the ACR Annual Meeting Planning Committee, is putting together another can’t-miss advocacy program for the 2018 Annual Meeting in Chicago; and
  • Ethan Craig, MD, Christina Downey, MD, Stephanie Ott, MD and Chap Sampson, MD, led GAC’s annual health policy update, which the ACR Board of Directors approved on Feb. 24. Check out the updated section on MACRA, PBMs, biosimilars and more.

Build RheumPAC & the Foundation
There are two ways you can help ensure the future of our profession: Invest in RheumPAC, which provides your advocacy team with critical relationships in Washington, D.C., and the Rheumatology Research Foundation, which, as you may know, is the largest private funder of rheumatology research and also funds much of the training for our future workforce. Donate today.

Pages: 1 2 3 | Single Page

Filed Under: Legislation & Advocacy Tagged With: ACR Government Affairs Committee, advocacy team, Angus Worthing, Bipartisan Budget Act of 2018, D.C. update, GAC, healthcare fixes, high drug costs, Part B drug costs

You Might Also Like:
  • ACR Leaders Outline Advocacy Victories, Threats
  • Challenges Rheumatologists Will Face in 2017
  • ACR Leads Coalition Response to HHS Proposed Drug Pricing Threats
  • The ACR Announces Advocacy Priorities for 2016

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.